Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-155 in advanced solid tumors
NCT03595059Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2018
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of mirzotamab clezutoclax in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and breast cancer (5 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Phase 2 Dose at 21 days and 1 more. Started Jul 2018; status: completed.
02
Drugs
mirzotamab clezutoclax
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT03595059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595059.